Jakrif-11 Xr Tablet

About Jakrif-11 Xr Tablet

Jakrif-11 XR Tablet contains 11 mg of tofacitinib and is made by Renata PLC. It belongs to a group of medicines called immunosuppressants.

There are 13 brands of Tofacitinib listed in Bangladesh. The lowest listed price is Tofacit 5 mg Tablet at ৳ 30.00 per unit.

What is Jakrif-11 Xr Tablet?

Jakrif-11 XR Tablet is a medicine that contains tofacitinib in a strength of 11 mg. It is classified as an immunosuppressant, which means it affects the immune system. The tablet is made by Renata PLC. This medicine is used to treat certain long-term inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is available only by prescription, and your doctor will decide if it is suitable for you. The extended-release tablet is designed to release the medicine gradually over time. Always follow your doctor's instructions and do not share this medicine with others.

Uses of Jakrif-11

Jakrif-11 XR Tablet is used for adults with moderately to severely active rheumatoid arthritis who have not responded well to or cannot tolerate methotrexate. It can be taken alone or with other disease-modifying antirheumatic drugs. It is also used for psoriatic arthritis, often in combination with nonbiologic DMARDs, and for ulcerative colitis. Your doctor will determine the right use for your condition.

How to use Jakrif-11

Take Jakrif-11 XR Tablet exactly as your doctor prescribes. The extended-release tablet should be swallowed whole and not crushed, split, or chewed. You may take it with or without food. The dose and how often you take it will be decided by your doctor based on your condition and other medicines you take. Do not change the dose or stop taking it without talking to your doctor first. If you miss a dose, ask your doctor or pharmacist what to do.

Side effects of Jakrif-11

The most common side effects reported in the first three months of treatment include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis (inflammation of the nose and throat). These are not all the possible side effects. Tell your doctor or pharmacist if you notice any side effects or if they bother you. Some side effects can be serious, so seek medical advice if you develop signs of infection or other concerning symptoms.

Safety and precautions

Jakrif-11 XR Tablet is not suitable for everyone. Avoid it during an active serious infection. It may increase the risk of gastrointestinal perforations, so use with caution if you are at risk. Your doctor may monitor your blood counts, liver enzymes, and lipids. Live vaccines should not be given while taking this medicine. It is pregnancy category C; there are no adequate studies in pregnant women, and it should be used only if the potential benefit justifies the potential risk to the fetus. It is not known if it passes into breast milk, so discuss breastfeeding with your doctor. Always tell your doctor about all your medical conditions and medicines before starting this treatment.

Frequently asked questions

What does the dosage form and strength mean?

Jakrif-11 is an extended-release (XR) tablet, meaning it releases the medicine gradually in the body. The strength is 11 mg of tofacitinib per tablet. Your doctor will decide the right dose and course for you.

What is Jakrif-11 used for and what kind of medicine is it?

Jakrif-11 XR Tablet is an immunosuppressant used for adults with rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by affecting the immune system to reduce inflammation. Your doctor will determine if it is right for your condition.

Is Jakrif-11 safe in pregnancy or breastfeeding?

It is pregnancy category C, meaning there are no adequate studies in pregnant women, and it should be used only if the benefit justifies the risk. It is not known if it passes into breast milk. Discuss pregnancy and breastfeeding with your doctor before taking this medicine.

What should I tell my doctor before starting Jakrif-11?

Tell your doctor about any active infections, liver or kidney problems, and all other medicines you take. Also mention if you are pregnant, planning pregnancy, or breastfeeding. Your doctor will decide if Jakrif-11 is suitable and may monitor your blood counts and liver enzymes.

Indications

Rheumatoid Arthritis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic ... Read moreRheumatoid Arthritis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).

Psoriatic Arthritis: Tofacitinib is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

Ulcerative Colitis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

Pharmacology

Rheumatoid arthritis is an autoimmune disease characterized by a dysregulation of pro-inflammatory cytokines including IL7, IL15, IL21, IL6, IFN-alpha, and IFN-beta. (3) Cytokines signalling results in tissue inflammation and joint damage by stimulating the recruitment and activation of immune cells via the janus kinase signalling pathway.

Tofacitinib is a partial and reversible janus kinase (JAK) inihibitor that will prevent the body from responding to cytokine signals. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. The JAK-STAT signalling pathway is involved in the transcription of cells involved in hematopoiesis, and immune cell function. Tofacitinib works therapeutically by inhibiting the JAK-STAT pathway to decrease the inflammatory response. However, there is evidence to suggest that it may also achieve efficacy via other pathways as well.

Dosage & Administration

Rheumatoid Arthritis: Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.

Psoriatic Arthritis (in combination with nonbiologic DMARDs): Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily.  Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.

Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.

Interaction

  • Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole)
  • Recommended dose is Tofacitinib 5 mg once daily: One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole)
  • Recommended dose is Tofacitinib 5 mg once daily Potent CYP inducers (e.g.Rifampin): May result in loss of or reduced clinical response.

Side Effects

The most commonly reported adverse reactions during the first 3 months in controlled clinical trials (occurring in greater than or equal to 2% of patients treated with Tofacitinib monotherapy or in combination with DMARDs) were upper respiratory tract infections, headache, diarrhea and nasopharyngitis.

Pregnancy & Lactation

Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Tofacitinib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is not known whether Tofacitinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother

Precautions & Warnings

  • Serious Infections: Avoid use of Tofacitinib during an active serious infection, including localized infections. 
  • Gastrointestinal Perforations: Use with caution in patients that may be at increased risk.
  • Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
  • Immunizations: Live vaccines: Avoid use with Tofacitinib.
  • Do not initiate Tofacitinib if absolute lymphocyte count <500 cells/mm3, an absolute neutrophil count (ANC) <1000 cells/mm3 or hemoglobin <9 gm/dL.

Storage Conditions

Store below 30°C. Protect from light & moisture. Keep all medicines out of the reach of children.

Alternative brands of Tofacitinib

Other brands with the same generic name, cheapest first.

Tofanib Tablet

5 mg

Tofacitinib

Globe Pharmaceuticals Ltd.

৳ 47.04 ৳ 48.00 2% off per unit

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.